Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
By Ben Glickman
Tyra Biosciences said it received Rare Pediatric Disease Designation from regulators for its potential treatment for a form of dwarfism.
The Carlsbad, Calif.-based biotechnology company said Thursday the U.S. Food and Drug Administration had granted the designation to TYRA-300 as a potential treatment of achondroplasia.
The company said achondroplasia is the most common form of dwarfism and has limited available therapies.
Tyra plans to submit an Investigational New Drug application to the FDA in the second half of 2024, which would allow the company to begin a Phase 2 clinical trial examining dose cohorts.
RPD designation is given by the FDA to potential drugs to treat rare serious or life-threatening diseases which primarily affect children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 18:05 ET (23:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks